Skip to main content

Dr. Ashley Cauthen, M.D.

Dermatology (Dermatology Physician)

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2008
Medicare patients seen, 2024
2,544

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2008Medical school: Florida State University College of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Dermatology Physician primary
    FL license ME112254

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Dermatology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
2,544
Services billed
21,399
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Destruction of precancer skin growth, 2-14 growths7,5951,261
Injection, tildrakizumab, 1 mg3,40011
Established patient office or other outpatient visit, 20-29 minutes3,2752,294
Destruction of precancer skin growth, 1 growth2,1131,597
Biopsy of related skin growth, first growth1,3721,097
Destruction of skin growth, 1-14 growths1,138954
Established patient office or other outpatient visit, 30-39 minutes794665
Biopsy of related skin growth, each additional growth610376
Application of ultraviolet light to skin59626
New patient office or other outpatient visit, 30-44 minutes308308

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 22 companies reported 184 payments worth $90,991 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$79,025
Travel and Lodging$7,693
Food and Beverage$4,168
Education$105

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 6, 2025Galderma Laboratories, L.P.
Jun 6, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Jun 6, 2025Galderma Laboratories, L.P.
Jun 6, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Aug 8, 2025Galderma Laboratories, L.P.
Aug 8, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Oct 29, 2025Galderma Laboratories, L.P.
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Sep 9, 2025Amgen Inc.
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Oct 20, 2025Amgen Inc.
Oct 20, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Mar 14, 2025Amgen Inc.
Mar 14, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
May 13, 2025Amgen Inc.
May 13, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Jun 30, 2025Amgen Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Apr 16, 2025Amgen Inc.
Apr 16, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
All 39 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Oct 29, 2025Galderma Laboratories, L.P.
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Oct 29, 2025Galderma Laboratories, L.P.
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
Oct 24, 2025Galderma Laboratories, L.P.
Oct 24, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
Oct 23, 2025Amgen Inc.
Oct 23, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to Saint Petersburg, FL · in-kind
$852
Oct 20, 2025Amgen Inc.
Oct 20, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Oct 20, 2025Amgen Inc.
Oct 20, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$650
Oct 7, 2025Regeneron Healthcare Solutions, Inc.
Oct 7, 2025
Education
DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind
$5.00
Sep 9, 2025Amgen Inc.
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Sep 9, 2025Amgen Inc.
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$650
Sep 5, 2025Amgen Inc.
Sep 5, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to Sarasota, FL · in-kind
$1,086
Aug 21, 2025Galderma Laboratories, L.P.
Aug 21, 2025
Travel and Lodging
NEMLUVIO · DERMATITIS · travel to LEESBURG, FL · in-kind
$39.20
Aug 21, 2025Galderma Laboratories, L.P.
Aug 21, 2025
Travel and Lodging
NEMLUVIO · DERMATITIS · travel to THE VILLAGES, FL · in-kind
$24.92
Aug 13, 2025Galderma Laboratories, L.P.
Aug 13, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
Aug 8, 2025Galderma Laboratories, L.P.
Aug 8, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Aug 8, 2025Galderma Laboratories, L.P.
Aug 8, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
Aug 1, 2025Galderma Laboratories, L.P.
Aug 1, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$600
Jul 1, 2025Janssen Biotech, Inc.
Jul 1, 2025
Education
TREMFYA · Immunology · in-kind
$99.99
Jun 30, 2025Amgen Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Jun 30, 2025Amgen Inc.
Jun 30, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$650
Jun 27, 2025Amgen Inc.
Jun 27, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to Tampa, FL · in-kind
$1,131
Jun 6, 2025Galderma Laboratories, L.P.
Jun 6, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
Jun 6, 2025Galderma Laboratories, L.P.
Jun 6, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$5,400
May 29, 2025Galderma Laboratories, L.P.
May 29, 2025
Travel and Lodging
NEMLUVIO · DERMATITIS · travel to CLEARWATER, FL · in-kind
$2,069
May 29, 2025Galderma Laboratories, L.P.
May 29, 2025
Travel and Lodging
NEMLUVIO · DERMATITIS · travel to CLEARWATER, FL · in-kind
$30.00
May 13, 2025Amgen Inc.
May 13, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
May 13, 2025Amgen Inc.
May 13, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$650
May 12, 2025Galderma Laboratories, L.P.
May 12, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
May 8, 2025Amgen Inc.
May 8, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to LAKELAND, FL · in-kind
$1,050
Apr 23, 2025Amgen Inc.
Apr 23, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$1,625
Apr 16, 2025Amgen Inc.
Apr 16, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Apr 16, 2025Amgen Inc.
Apr 16, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$650
Apr 15, 2025Amgen Inc.
Apr 15, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to SARASOTA, FL
$199
Apr 11, 2025Amgen Inc.
Apr 11, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to SARASOTA, FL · in-kind
$281
Apr 2, 2025Galderma Laboratories, L.P.
Apr 2, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
Mar 20, 2025Galderma Laboratories, L.P.
Mar 20, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$3,600
Mar 14, 2025Amgen Inc.
Mar 14, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$3,900
Mar 14, 2025Amgen Inc.
Mar 14, 2025
Compensation for services other than consulting (speaking, faculty)
OTEZLA · Inflammation
$650
Mar 5, 2025Amgen Inc.
Mar 5, 2025
Travel and Lodging
OTEZLA · Inflammation · travel to CLERMONT, FL · in-kind
$932
Feb 10, 2025Galderma Laboratories, L.P.
Feb 10, 2025
Compensation for services other than consulting (speaking, faculty)
NEMLUVIO · DERMATITIS
$2,700

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 18 industry-funded studies in 2025, from 7 companies. The companies reported $782,110 in research payments for these studies, mostly to the institutions running them.

  • TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
    Takeda Pharmaceuticals U.S.A., Inc.
  • A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic hand and foot d…
    Eli Lilly and Company
  • A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
    AbbVie Inc. · Active, not recruiting · NCT06468228
  • Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
    Eli Lilly and Company · Completed · NCT06588283
  • A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
    Incyte Corporation
  • A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
    Incyte Corporation
  • A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Mod…
    Janssen Research & Development, LLC
  • A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
    Janssen Research & Development, LLC
  • M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
    AbbVie Inc.
  • A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
    Takeda Pharmaceuticals U.S.A., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Ocala

Sources

NPI registry (CMS NPPES, November 2026; record last updated January 25, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1720254071. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.